Sonida Senior Living enters the post-earnings stretch with an unusual combination: shorts piling in at the fastest pace in months while the dominant shareholder doubles down and a bellwether analyst lifts his target to a new high.
Short interest has become the defining tension this week. Measured against the free float, it has jumped from roughly 1.4% in mid-April to 3.0% today — more than doubling in less than a month. The most dramatic acceleration came after the Q1 earnings print on May 11, when shares sold off 3%. In the five trading days through May 12, shorts added 26% to their position, the sharpest weekly build since April. At around 972,000 shares short, the absolute level remains modest for a small-cap name, but the rate of change is not. Borrow is cheap — cost to borrow is just 0.55% — and availability remains wide, meaning the lending market is putting up no friction to further shorting. That combination of rising conviction and easy borrow is worth noting.
Options tell a quieter story. The put/call ratio at 0.07 is barely above its 20-day mean of 0.057, suggesting options traders have not rushed to hedge alongside the short sellers. The ratio has drifted up slightly from near-zero levels in mid-April, but the z-score of 0.33 puts it well inside one standard deviation. For context, the 52-week PCR high is 0.99 — this week's reading is nowhere near that. On balance, derivatives positioning is calm rather than defensive.
The Street is leaning constructive, even post-miss. On May 13, Cantor Fitzgerald's Richard Anderson — who initiated coverage at $36 in April — raised his target to $42 while maintaining Overweight, the most bullish call on the stock. RBC Capital reaffirmed its buy-equivalent rating on May 12. Baird sits at Neutral with a $37 target, essentially in line with the current price of $37.12. Morgan Stanley holds Equal-Weight with a $31 target, the lone cautious voice with meaningful coverage. The consensus mean target of $37.25 is nearly spot-on with the current price, meaning the Street as a whole is not pricing in much upside — but the direction of travel on targets has been firmly higher over recent weeks.
The ownership picture adds another layer of complexity. Conversant Capital — already the controlling shareholder at 30.4% of shares — bought over $100 million worth of stock in March at prices around $26.74, a 28% discount to current levels. That conviction trade has aged well, with the stock up 14% over the past month. Meanwhile, CEO Brandon Ribar and CFO Kevin Detz both sold shares in early April near $32 — well below current levels — in what appear to be routine plan-driven disposals rather than directional calls. Net insider activity over 90 days is heavily positive at over $100 million, entirely driven by Conversant's block purchases. The stock's 90-day net position is dominated by one firm that controls nearly a third of the company.
The Q1 result that triggered this week's short build deserves context. Revenue came in marginally below estimates at $122.6 million, but the EPS miss was severe: $(2.39) against a $(0.43) estimate. Management flagged the CHP portfolio acquisition as a boost to revenue while pointing to mid-6x leverage as the medium-term target, with 11 further community transitions planned for summer. The market has taken a nuanced view — the stock is flat to slightly up on the week despite the initial 3% decline on earnings day. The next earnings event is June 11.
The setup heading into June is a study in contradictions: a dominant insider bought heavily at lower prices, a freshly initiated analyst is the most bullish on the Street, and shorts are rebuilding at pace after an earnings miss that widened losses sharply. Whether the short rebuild reflects concern about the leverage trajectory or the pace of the CHP integration is the question worth tracking into the next print.
See the live data behind this article on ORTEX.
Open SNDA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
